Author

Gert Van Assche 1

1 University Hospitals Leuven,Leuven,Belgium

A DRUG-RESISTANT ASSAY CAN BETTER DIRECT THE NEED FOR ADALIMUMAB DOSE-ESCALATION AFTER INDUCTION THERAPY IN ANTI-TNF NAÏVE PATIENTS WITH CROHN’S DISEASE

Gitte Moors, Bram Verstockt, Sumin Bian, Sophie Tops, Vera Ballet, Gert Van Assche, Severine Vermeire, Ann Gils, Marc Ferrante

CORRELATION BETWEEN CLINICAL AND ENDOSCOPIC ENDPOINTS AND REMISSION PER INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORE IN PATIENTS WITH CROHN'S DISEASE: DATA FROM CELEST

Remo Panaccione, Stefan Schreiber, Gert Van Assche, Walter Reinisch, Edouard Louis, Timothy Zisman, Bruce Yacyshyn, Subrata Ghosh, Shariar Sedghi, Sasikiran Goteti, Wan-Ju Lee, Ana P. Lacerda

CORRELATION OF ENDOSCOPIC FINDINGS WITH SERUM DRUG CONCENTRATIONS AND NEED FOR RESCUE THERAPY: SUBANALYSIS OF THE TROUGH CONCENTRATION ADAPTED INFLIXIMAB TREATMENT (TAXIT) TRIAL

Lieven Pouillon, Marc Ferrante, Gert Van Assche, Maja Noman, Ann Gils, Severine Vermeire

Corticosteroid Sparing Effects of Ustekinumab Therapy in Ulcerative Colitis Patients: Results From the UNIFI Program

Silvio Danese, Bruce E. Sands, Laurent Peyrin-Biroulet, C Marano, Christopher O’Brien, Hongyan Zhang, Alessandra Nunes Faria Oortwijn, David Rowbotham, Rupert W Leong, Ramesh P. Arasaradnam, Gert Van Assche, William Sandborn, Remo Panaccione

DOSE DE-ESCALATION TO ADALIMUMAB 40 MG EVERY THREE WEEKS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE COHORT ANALYSIS

Sophie Van Steenbergen, Sumin Bian, Vera Ballet, Severine Vermeire, Gert Van Assche, Ann Gils, Marc Ferrante

Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 2 Years: UNIFI Long-term Extension

Bruce E. Sands, William Sandborn, Remo Panaccione, Christopher D. O'Brien, Hongyan Zhang, Jewel Johanns, Yiying Zhou, Ilia Tikhonov, Laurent Peyrin-Biroulet, Gert Van Assche, Silvio Danese, Stephan Targan, Maria T. Abreu, Tadakazu Hisamatsu, Ellen Scherl, Rupert W Leong, David Rowbotham, Ramesh P. Arasaradnam, Colleen W.

EVALUATING EFFICACY, SAFETY AND PHARMACOKINETICS AFTER SWITCHING FROM INFLIXIMAB ORIGINATOR TO BIOSIMILAR CT-P13: RESULTS FROM A LARGE TERTIARY REFERRAL CENTER

Michiel Bronswijk, Annick Moens, Matthias Lenfant, Griet Compernolle, Gert Van Assche, Severine Vermeire, Ann Gils, Marc Ferrante

Evolution of endoscopic lesions in patients admitted for acute severe ulcerative colitis responding to infliximab or cyclosporine: sub-study from the CYSIF trial

David Laharie, Arnaud Bourreille, Julien Branche, Matthieu Allez, Yoram Bouhnik, Jerome Filippi, Frank Zerbib, Guillaume Savoye, Lucine Vuitton, Jacques Moreau, Aurelien Amiot, Laurent Beaugerie, Elena Ricart, Olivier Dewit, Antonio López San Román, Mathurin Fumery, Franck Carbonnel, Anthony Buisson, Benoit Coffin, Xavie

HIGHER EXPOSURE BUT LOWER RESPONSE RATE TO INFLIXIMAB INDUCTION THERAPY IN ELDERLY PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Erwin Dreesen, Valerie De Weerdt, Thomas Van Stappen, Eliana Peeters, Triana Lobaton Ortega, Gert Van Assche, Severine Vermeire, Ann Gils, Marc Ferrante

INFLIXIMAB DOSE DOUBLING IS EFFECTIVE FOR OPTIMIZING TROUGH CONCENTRATIONS AND REGAINING CLINICAL RESPONSE IN PATIENTS WITH CROHN?S DISEASE

Erwin Dreesen, Vera Ballet, Griet Compernolle, Gert Van Assche, Marc Ferrante, Severine Vermeire, Ann Gils

Item 1 - 10 / 17
1
2